The Global X-linked Hypophosphatemia Market is driven by increasing prevalence of metabolic bone diseases
X-linked Hypophosphatemia (XLH) is a rare genetic disorder causing impaired bone mineralization. It is characterized by low levels of phosphate in the blood and bones resulting in rickets or osteomalacia. Those affected may experience bone pain, waddling gait, bowed legs, short stature and fractures. Existing treatments for XLH mainly include phosphate and vitamin D supplements, however, they have limitations in completely correcting the biochemical abnormalities or clinical manifestations of the disease. The development of more targeted therapies has accelerated in recent years to effectively manage XLH.
The X-linked hypophosphatemia market is estimated to be valued at USD 1.5 Bn in 2024 and is expected to reach USD 2.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
Key players operating in the X-linked Hypophosphatemia are Kyowa Hakko Kirin, Ultragenyx Pharmaceutical, Nestlé Health Science, and Alexion Pharmaceuticals.
There is growing demand for more effective treatment options to better manage symptoms of X-linked Hypophosphatemia Market and improve quality of life. Globally, increasing healthcare expenditures and efforts by biopharma companies to develop novel therapies have boosted the XLH market.
Major pharmaceutical manufacturers are also expanding their operations across countries with high prevalence of metabolic bone diseases like the United States, Canada, Japan and European countries. This is expected to facilitate better access to diagnosis and management of XLH worldwide over the coming years.
Get more insights on - X-linked Hypophosphatemia Market
Get this Report in Japanese Language: X連鎖性低リン血症市場
Get this Report in Korean Language: X-연관 저인산혈증 시장
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian